Floatz logo

Umbellatine

Atherosclerotic Cardiovascular Disease

China National Center for Cardiovascular DiseasesSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Atherosclerotic Cardiovascular Disease cohort.

Asset / SponsorPhaseRating
Eicosapentaenoic Acid Ethyl Ester
Kobe University
Phase 4BB
Maridebart Cafraglutide
Amgen
Phase 3B
Orforglipron
Eli Lilly and Company
Phase 3B
Inclisiran
Novartis Pharmaceuticals
Phase 3B
Tirzepatide
Brigham and Women's Hospital
Phase 4B

View all 16 →

Same molecule, other indications

Umbellatine is also rated in:

inherited lipid metabolism disorderActive
BBB
Indicative · Phase 4
72 / 100
View asset →
abdominal obesity-metabolic syndromeActive
BB
Indicative · Phase 4
69 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseActive
BB
Indicative · Phase 4
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →